eXoZymes Secures $2.03M NIH Grant for Cannabinoid Analog Development, Boosting Non-Dilutive Funding
EXOZ is trading near its 52-week low of $6.33 (14% above the low).
Summary
EXOZYMES has been awarded a $2.03 million non-dilutive NIH SBIR Phase IIB grant to advance its cannabinoid analog development program. This funding is critical for the company, which recently disclosed substantial doubt about its ability to continue as a going concern in its 10-K and 10-Q filings, and has relied on multiple dilutive equity offerings, including a $5.3 million unit offering finalized earlier this month. The grant provides essential capital for R&D over two years and increases the company's total non-dilutive funding to $19.7 million, validating its cell-free manufacturing platform.
At the time of this announcement, EXOZ was trading at $7.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $67.1M. The 52-week trading range was $6.33 to $18.40. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.